Index - P/E - EPS (ttm) -2.31 Insider Own 10.24% Shs Outstand 46.41M Perf Week 6.80%
Market Cap 1.79B Forward P/E - EPS next Y -1.01 Insider Trans 0.00% Shs Float 41.85M Perf Month 5.19%
Income -97.56M PEG - EPS next Q -0.23 Inst Own 83.91% Short Float 10.24% Perf Quarter -5.41%
Sales 0.00M P/S - EPS this Y -12.35% Inst Trans - Short Ratio 7.04 Perf Half Y -25.35%
Book/sh 9.22 P/B 4.16 EPS next Y -10.83% ROA -27.69% Short Interest 4.29M Perf Year 44.11%
Cash/sh 9.36 P/C 4.09 EPS next 5Y - ROE -29.29% 52W Range 24.14 - 75.02 Perf YTD -5.99%
Dividend Est. - P/FCF - EPS past 5Y - ROI -22.51% 52W High -48.92% Beta -3.72
Dividend TTM - Quick Ratio 19.05 Sales past 5Y 0.00% Gross Margin - 52W Low 58.74% ATR (14) 2.11
Dividend Ex-Date - Current Ratio 19.05 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 54.04 Volatility 6.69% 5.53%
Employees 93 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 75.70
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 25.68% Payout - Rel Volume 1.27 Prev Close 36.38
Sales Surprise - EPS Surprise 2.21% Sales Q/Q - Earnings May 09 AMC Avg Volume 609.30K Price 38.32
SMA20 1.57% SMA50 -0.59% SMA200 -13.04% Trades
Volume 767,947 Change 5.33%
Date
Action
Analyst
Rating Change
Price Target Change
May-21-24 Initiated JP Morgan
Overweight
$65
Apr-09-24 Initiated Cantor Fitzgerald
Overweight
$65
Oct-19-23 Initiated JMP Securities
Mkt Outperform
$90
Jul-27-23 Initiated Piper Sandler
Overweight
$58
May-25-23 Resumed Jefferies
Buy
$34 → $41
Feb-28-23 Initiated SVB Securities
Outperform
$33
Feb-28-23 Initiated Jefferies
Buy
$34
Feb-28-23 Initiated Guggenheim
Buy
$50
Feb-28-23 Initiated BMO Capital Markets
Outperform
$40
May-21-24 07:44AM
May-09-24 10:56PM
04:05PM
10:34AM
Apr-24-24 06:33AM
09:37AM
Loading…
Mar-30-24 09:37AM
Mar-15-24 10:53AM
Mar-08-24 04:05PM
08:30AM
Jan-22-24 05:24AM
Dec-25-23 07:45AM
Dec-22-23 04:21PM
Dec-18-23 04:06PM
(Investor's Business Daily) -42.82%
01:03PM
(The Wall Street Journal)
11:29AM
09:22AM
Loading…
09:22AM
(Investor's Business Daily)
07:30AM
07:30AM
06:23AM
Dec-11-23 12:26PM
Nov-29-23 02:28PM
02:30AM
Nov-27-23 09:50AM
Nov-26-23 04:44PM
Nov-14-23 04:10PM
Nov-03-23 05:20AM
Oct-19-23 08:45AM
Oct-06-23 08:45AM
Oct-02-23 03:48PM
Sep-29-23 04:04PM
(Investor's Business Daily) +34.56%
12:50PM
Loading…
12:50PM
11:19AM
10:24AM
09:34AM
(Investor's Business Daily)
07:32AM
07:30AM
Aug-10-23 04:05PM
Aug-03-23 05:32PM
Jul-16-23 07:00AM
(The Wall Street Journal)
Jun-27-23 02:10PM
01:35PM
08:12AM
Jun-26-23 09:05PM
Jun-16-23 08:00AM
Jun-13-23 06:10AM
Jun-12-23 10:15AM
Jun-07-23 08:30AM
May-31-23 04:30PM
May-25-23 04:30PM
May-18-23 04:30PM
May-11-23 04:30PM
May-03-23 06:59AM
Mar-30-23 04:30PM
Feb-07-23 04:00PM
Feb-06-23 03:17PM
(American City Business Journals)
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.
Index S&P 500 P/E 44.32 EPS (ttm) 5.90 Insider Own 8.80% Shs Outstand 739.20M Perf Week -1.30%
Market Cap 193.62B Forward P/E 30.20 EPS next Y 8.66 Insider Trans -0.28% Shs Float 675.54M Perf Month 4.39%
Income 4.40B PEG 5.89 EPS next Q 1.58 Inst Own 82.03% Short Float 0.82% Perf Quarter 2.98%
Sales 26.23B P/S 7.38 EPS this Y 0.14% Inst Trans -0.21% Short Ratio 2.11 Perf Half Y 19.99%
Book/sh 72.16 P/B 3.62 EPS next Y 14.04% ROA 5.28% Short Interest 5.54M Perf Year 28.21%
Cash/sh 9.49 P/C 27.54 EPS next 5Y 7.52% ROE 8.47% 52W Range 182.09 - 268.98 Perf YTD 12.99%
Dividend Est. 0.96 (0.37%) P/FCF 34.84 EPS past 5Y 11.31% ROI 6.30% 52W High -2.82% Beta 0.86
Dividend TTM 1.05 (0.40%) Quick Ratio 1.51 Sales past 5Y 8.35% Gross Margin 58.35% 52W Low 43.56% ATR (14) 4.19
Dividend Ex-Date Jun 28, 2024 Current Ratio 1.85 EPS Y/Y TTM -36.66% Oper. Margin 21.32% RSI (14) 60.60 Volatility 1.25% 1.48%
Employees 63000 Debt/Eq 0.36 Sales Y/Y TTM -15.25% Profit Margin 16.78% Recom 1.65 Target Price 274.28
Option/Short Yes / Yes LT Debt/Eq 0.31 EPS Q/Q -25.02% Payout 16.45% Rel Volume 1.12 Prev Close 267.19
Sales Surprise 3.09% EPS Surprise 11.84% Sales Q/Q -19.13% Earnings Apr 23 BMO Avg Volume 2.62M Price 261.40
SMA20 2.83% SMA50 4.71% SMA200 12.86% Trades
Volume 2,901,184 Change -2.17%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-17-24 Upgrade HSBC Securities
Hold → Buy
$280
Jan-24-24 Downgrade Barclays
Overweight → Equal Weight
$240
Dec-18-23 Initiated HSBC Securities
Hold
Dec-13-23 Resumed Wolfe Research
Peer Perform
Dec-07-23 Downgrade Goldman
Buy → Neutral
$215 → $205
Jul-19-23 Initiated Raymond James
Outperform
$270
May-01-23 Initiated SVB Securities
Outperform
$300
Apr-26-23 Downgrade BofA Securities
Buy → Neutral
$310 → $250
Apr-18-23 Upgrade Wells Fargo
Equal Weight → Overweight
$275 → $285
Jan-05-23 Downgrade Credit Suisse
Outperform → Neutral
$315 → $300
Dec-14-22 Initiated Deutsche Bank
Buy
$310
Oct-24-22 Downgrade The Benchmark Company
Buy → Hold
$325
Aug-25-22 Initiated Credit Suisse
Outperform
$340
Aug-17-22 Resumed Bernstein
Outperform
$330 → $340
Jul-20-22 Initiated UBS
Buy
$297
Jun-01-22 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$299 → $310
Apr-25-22 Downgrade Wells Fargo
Overweight → Equal Weight
$265
Jan-11-22 Initiated Bernstein
Outperform
$365
Oct-15-21 Resumed Cowen
Outperform
$350
Sep-10-21 Reiterated BofA Securities
Buy
$340 → $360
Show Previous Ratings
May-23-24 11:30AM
May-17-24 07:01PM
May-15-24 10:43AM
08:00AM
May-09-24 01:13PM
07:00AM
Loading…
07:00AM
May-08-24 09:00AM
May-07-24 04:45PM
04:15PM
May-06-24 02:50PM
May-05-24 08:19AM
May-03-24 09:06AM
May-01-24 08:00AM
Apr-26-24 03:09PM
Apr-25-24 07:00PM
09:52AM
Loading…
Apr-24-24 09:52AM
03:01AM
01:02AM
Apr-23-24 10:17PM
(Thomson Reuters StreetEvents) +7.21%
04:41PM
12:21PM
(The Wall Street Journal)
12:07PM
(Associated Press Finance)
11:39AM
11:33AM
(Investor's Business Daily)
11:29AM
10:53AM
10:44AM
09:30AM
07:31AM
07:10AM
06:59AM
Loading…
06:59AM
06:55AM
06:26AM
06:07AM
(Associated Press Finance)
06:00AM
05:37AM
Apr-19-24 09:52AM
Apr-18-24 04:27PM
12:10PM
10:58AM
09:15AM
Apr-17-24 08:00AM
Apr-13-24 12:16PM
Apr-12-24 12:30PM
Apr-11-24 04:30PM
12:19PM
Apr-05-24 06:00PM
Apr-04-24 09:00AM
08:00AM
Apr-02-24 06:15PM
Mar-28-24 03:41AM
Mar-27-24 06:00PM
09:30AM
08:00AM
Mar-26-24 06:15PM
Mar-21-24 04:15PM
10:25AM
09:00AM
Mar-20-24 06:00PM
08:00AM
Mar-18-24 06:15PM
Mar-13-24 10:23AM
08:05AM
Mar-12-24 06:00PM
Mar-11-24 06:15PM
Mar-06-24 06:00AM
Mar-05-24 06:00PM
Mar-04-24 09:06AM
Mar-02-24 10:42AM
Mar-01-24 09:00AM
Feb-29-24 11:30AM
Feb-28-24 06:00PM
Feb-27-24 04:15PM
Feb-25-24 02:38PM
Feb-22-24 09:01PM
04:15PM
Feb-21-24 04:15PM
Feb-17-24 01:28PM
Feb-12-24 03:03PM
Feb-09-24 01:40AM
Feb-05-24 07:30AM
Feb-01-24 11:08AM
Jan-30-24 11:14PM
(Thomson Reuters StreetEvents)
01:26PM
11:44AM
11:08AM
09:30AM
07:10AM
06:34AM
06:17AM
(Associated Press Finance)
06:00AM
Jan-29-24 12:56PM
08:36AM
07:30AM
Jan-26-24 08:10AM
Jan-25-24 09:15AM
Jan-23-24 10:00AM
Jan-22-24 06:00PM
Jan-19-24 04:27AM
Jan-17-24 12:10PM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Blair Rainer President & CEO May 16 '24 Sale 265.00 9,005 2,386,325 106,990 May 17 05:08 PM King William SVP, Strategic Development May 15 '24 Option Exercise 50.37 12,623 635,821 55,208 May 17 05:10 PM Blair Rainer President & CEO May 14 '24 Option Exercise 59.91 19,085 1,143,435 135,080 May 15 05:00 PM Blair Rainer President & CEO May 14 '24 Sale 255.00 19,085 4,866,675 115,995 May 15 05:00 PM McGrew Matthew EVP & Chief Financial Officer May 10 '24 Option Exercise 61.25 25,174 1,541,794 45,338 May 13 05:01 PM McGrew Matthew EVP & Chief Financial Officer May 10 '24 Sale 253.05 46,377 11,735,856 29,407 May 13 05:01 PM SPOON ALAN G Director May 02 '24 Option Exercise 52.56 3,289 172,870 116,910 May 03 05:03 PM SPOON ALAN G Director May 02 '24 Sale 243.58 708 172,455 116,202 May 03 05:03 PM Weidemanis Joakim Executive Vice President Apr 25 '24 Option Exercise 58.48 22,433 1,311,882 112,845 Apr 26 05:00 PM Weidemanis Joakim Executive Vice President Apr 25 '24 Sale 250.46 22,433 5,618,569 90,412 Apr 26 05:00 PM Blair Rainer President & CEO Apr 24 '24 Option Exercise 59.91 38,170 2,286,870 154,165 Apr 25 05:00 PM Blair Rainer President & CEO Apr 24 '24 Sale 249.22 47,175 11,756,725 115,995 Apr 25 05:00 PM Ellis Brian W Senior Vice President - GC Apr 24 '24 Sale 250.01 4,000 1,000,040 29,830 Apr 25 05:00 PM Raskas Daniel SVP - Corporate Development Feb 26 '24 Option Exercise 58.48 23,757 1,389,309 61,859 Feb 27 05:01 PM Raskas Daniel SVP - Corporate Development Feb 26 '24 Sale 252.00 23,757 5,986,764 38,102 Feb 27 05:01 PM LOHR WALTER G Director Feb 15 '24 Option Exercise 52.56 3,289 172,870 17,418 Feb 16 05:01 PM LOHR WALTER G Director Feb 15 '24 Sale 251.15 3,289 826,032 14,129 Feb 16 05:01 PM Couchara Georgeann SVP, Human Resources Feb 13 '24 Option Exercise 70.71 2,622 185,414 6,022 Feb 14 05:00 PM Couchara Georgeann SVP, Human Resources Feb 13 '24 Sale 242.67 2,622 636,290 4,244 Feb 14 05:00 PM List Teri Director Feb 06 '24 Option Exercise 52.56 3,289 172,870 23,015 Feb 08 05:00 PM List Teri Director Feb 06 '24 Sale 248.32 3,289 816,724 19,726 Feb 08 05:00 PM Gutierrez-Ramos Jose-Carlos SVP, Chief Science Officer Aug 21 '23 Sale 250.54 590 147,819 6,939 Aug 22 05:00 PM Raskas Daniel SVP - Corporate Development Jul 28 '23 Option Exercise 56.70 11,213 635,777 49,501 Aug 01 05:03 PM Zerhouni Elias A. Director Jul 28 '23 Option Exercise 50.80 3,490 177,292 30,523 Aug 01 05:02 PM SCHWIETERS JOHN T Director Jul 28 '23 Option Exercise 50.80 3,490 177,292 22,583 Aug 01 05:02 PM FILLER LINDA Director Jul 28 '23 Option Exercise 59.17 2,922 172,895 41,074 Aug 01 05:00 PM Raskas Daniel SVP - Corporate Development Jul 28 '23 Sale 260.65 11,213 2,922,652 38,288 Aug 01 05:03 PM FILLER LINDA Director Jul 28 '23 Sale 260.25 10,190 2,651,978 38,152 Aug 01 05:00 PM Weidemanis Joakim Executive Vice President Jul 26 '23 Option Exercise 56.70 22,439 1,272,291 111,128 Jul 27 05:01 PM List Teri Director Jul 26 '23 Option Exercise 50.80 3,490 177,292 20,984 Jul 27 05:00 PM Weidemanis Joakim Executive Vice President Jul 26 '23 Sale 263.42 22,439 5,910,832 88,689 Jul 27 05:01 PM List Teri Director Jul 26 '23 Sale 263.30 3,490 918,917 17,494 Jul 27 05:00 PM Raskas Daniel SVP - Corporate Development May 31 '23 Option Exercise 57.90 19,847 1,149,141 58,520 Jun 01 05:00 PM Raskas Daniel SVP - Corporate Development May 31 '23 Sale 228.50 19,847 4,535,040 38,673 Jun 01 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
